EUVIMEDDescubrir EUVIMED
QuerschnittstudieOpen access

Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study

Duygu Islek iD, Travis Sanchez iD, Jennifer L Glick iD, Jeb Jones iD, Keith Rawlings iD, Supriya Sarkar iD, Patrick S Sullivan iD, Vani Vannappagari iD

JMIR Public Health and Surveillance · 2024-11-13 · 10 · e62801

DOI: 10.2196/62801 ↗

At a glance

Querschnittstudie in JMIR Public Health and Surveillance, published online on 2024-11-13. Written by Duygu Islek and 7 co-authors. Institution: Rollins School of Public Health, Emory University, Atlanta, GA, United States. Major MEDLINE topics: Pre-Exposure Prophylaxis, HIV Infections, Homosexuality, Male. Cited 13 times so far (Crossref); 59 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Background

Long-acting (LA) injectable preexposure prophylaxis (PrEP) and on-demand PrEP may improve overall PrEP uptake among men who have sex with men (MSM), but little is understood about the PrEP option preferences of MSM in practical scenarios where they may choose between various PrEP options.

Objective

This study aims to examine the preferences for starting various PrEP options among a US nationwide online convenience sample of MSM from September 2021 to February 2022.

Methods

Participants reporting no prior HIV diagnosis were provided brief descriptions of each PrEP option and were asked, “If [PrEP option] were available from your local doctor and you could access it for free, would you go to your doctor in the next month to start [PrEP option]?” Those who said “yes” to multiple options were asked to rank them in order of preference. MSM currently taking daily oral (DO) PrEP were asked whether they would switch to on-demand or LA PrEP options. Log binomial models were created to examine the association between willingness to start or switch to on-demand and LA PrEP with various sociodemographic and behavioral factors.

Results

In the analytic sample (N=7760), among the participants who did not use any PrEP in the past 12 months (n=5108, 66%), 54% (n=2445) reported willingness to start at least 1 PrEP option and 41% (n=1845) of participants showed interest in starting multiple PrEP options. Overall, the highest willingness was reported for on-demand PrEP (n=2235, 44%), followed by DO PrEP (n=2174, 43%) and LA PrEP (n=1482, 29%). LA PrEP was ranked first among those interested in multiple options. Characteristics associated with ranking LA PrEP as a first option to start PrEP versus DO or on-demand PrEP were region of residence (residing in the West vs Northeast), report of sexually transmitted infection diagnosis in the past year, report of illicit drug use other than marijuana in the past year, and prior awareness of LA PrEP. Among current DO PrEP users (n=2379, 31%), 58% (n=1386) were willing to switch to on-demand or LA PrEP, and LA PrEP was ranked first among participants who were open to switching to both options. Willingness to switch to LA PrEP was higher among those who used illicit drugs other than marijuana in the past year, who heard of LA PrEP prior to the survey, and those who took 15 or less doses of oral PrEP in the last 30 days.

Conclusions

LA PrEP was the highest-ranked option among most MSM who were willing to try multiple options or switch from DO PrEP. These findings highlight that LA PrEP might fill coverage gaps among MSM who use illicit drugs, have had a recent sexually transmitted infection diagnosis, and have less than optimal DO PrEP adherence.

Subjects

MeSH terms (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsHomosexuality, MaleHumansMaleCross-Sectional StudiesAdultUnited StatesMiddle AgedYoung AdultPatient PreferenceAdolescentSurveys and Questionnaires

Author keywords

HIVHIV preventionHIV treatmentUnited Statesadherencegayillicit drug useinjectablelong-actingmen who have sex with menpreexposure prophylaxisreproductive healthsexual behaviorsexually transmitted infectionsociodemographic

Authors and institutions

  • Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Community Health Science & Policy (CHSP), LSUHSC, New Orleans, LA, United States.
  • ViiV Healthcare, Durham, NC, United States.

ORCID profiles: Duygu Islek, Travis Sanchez, Jennifer L Glick, Jeb Jones, Keith Rawlings, Supriya Sarkar, Patrick S Sullivan, Vani Vannappagari

Funding

  • NIAID NIH HHS

Cite

APA

Islek, D., Sanchez, T., Glick, J. L., Jones, J., Rawlings, K., Sarkar, S., Sullivan, P. S., & Vannappagari, V. (2024). Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study. JMIR Public Health and Surveillance, 10, e62801. https://doi.org/10.2196/62801

Vancouver

Islek D, Sanchez T, Glick JL, Jones J, Rawlings K, Sarkar S, et al. Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study. JMIR Public Health and Surveillance. 2024;10:e62801. doi:10.2196/62801

BibTeX
@article{Islek2024,
  author = {Islek, Duygu and Sanchez, Travis and Glick, Jennifer L and Jones, Jeb and Rawlings, Keith and Sarkar, Supriya and Sullivan, Patrick S and Vannappagari, Vani},
  title = {Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study},
  journal = {JMIR Public Health and Surveillance},
  year = {2024},
  volume = {10},
  pages = {e62801},
  doi = {10.2196/62801}
}
Start for free →